Background
Lung cancer will be diagnosed in approximately 200,000 Americans in 2013 and unfortunately remains the leading cause of cancer-related death in both men and women in the United States [1] . Among the subtypes of lung cancer, non-small cell lung cancer (NSCLC) is the most prevalent, accounting for 85% of all new cases.
Lung cancer is more common in older individuals, with an average age at diagnosis of 68 years and about a third of patients over 70 years of age [2] . Recent reports have suggested that there may be a rise in the number of young patients with NSCLC, particularly females [3, 4] .
There have been numerous papers focused on young NSCLC patients, each with varying definitions of "young" [5] [6] [7] [8] . Some of these studies attempted to compare outcomes between younger and older NSCLC patients. Results have thus far been conflicting. For example, in a small study of patients less than 40 years of age, the authors concluded that ". . . young patients tend to present with advanced disease at diagnosis, resulting in an extremely poor survival" [9] . A Greek study of NSCLC patients <45 years of http://dx.doi.org/10.1016/j.lungcan.2014.04.007 0169-5002/© 2014 Elsevier Ireland Ltd. All rights reserved. The asterisk (*) refers to statistically significant p values.
age suggested that outcomes are no different between younger and older patients [10] . Some community-based and national registry analyses of all forms of bronchogenic carcinoma have found improved outcomes in younger cohorts [18, 19] . A more recent surveillance, epidemiology, and end results (SEER) study of NSCLC patients <40 years of age concluded that "despite presenting with stage IV disease more often, the overall and cancer-specific survivals are better in (the) younger than in the older cohort" [7] . Many of these prior studies attempted to define clinical characteristics predictive of outcome for young NSCLC patients. However, most of these papers had very limited sample sizes and/or were derived from single institution databases, hence limiting their generalizability [6, 9, 11] .
In order to provide a more modern context of the epidemiologic characteristics and survival outcomes of younger patients with NSCLC while employing a more robust sample size, we analyzed the California Cancer Registry (CCR), a large database of all cancer cases diagnosed in California since 1988. We hypothesized that baseline variables predictive of outcome would be identified in young patients (here defined as <50 years of age) that differ from older patients, and that these patients will have better survival outcomes compared to those 50 years or older.
Methods
The objectives of the present study are (1) to describe the demographic characteristics and epidemiologic trends in the NSCLC population in the CCR from 1998 to 2008 with a focus on younger patients (<50 years of age); (2) to assess cause-specific survival (CSS, the primary outcome measure) in this younger cohort, and (3) to develop multivariate logistic regression survival models (adjusted for relevant variables) in order to identify baseline features prognostic CSS in younger patients with NSCLC.
We collected data from the CCR, a statewide cancer surveillance database that obtains information on every cancer patient in California from eight different regional registries [12] . Hospitals and other facilities that provide treatment and care for any cancer patients residing in California report to the Chronic Disease Surveillance & Research Branch of the California Department of Public Health. The cases included in these analyses were any stage NSCLC diagnosed between January 1, 1998 and December 31, 2009, and were reported to the Cancer Surveillance Program as of October 2011. Lung cancer was defined using the relevant International Classification of Diseases -Oncology (ICDO)-2 and ICDO-3 site codes. The version of CCR utilized in this study had all personal health identifiers removed, and therefore institutional review board approval was not necessary per CCR and UC Davis policy.
Descriptive statistics were used to describe the demographic variables of the cohort. In univariate analysis, continuous variables were compared using the Student's t-test, while categorical variables were compared using the Chi-square test. The primary outcome variable was CSS. The Kaplan-Meier method was used to determine survival, and the Log-rank test to compare survival proportions between groups. Multivariate analysis was performed with Cox proportional hazards models that evaluated predictors of CSS in young NSCLC patients. In order to formally determine differential effects of predictive covariates between the two age groups, tests for interaction were performed between age and each of the predictive covariates in the Cox model (e.g., age * histology, age * stage, age * race, etc). If significant interactions were identified, specific hazard ratios, confidence intervals, and P-values only for those interactions were calculated. All the analyses were performed using SAS 9.3 (SAS, Cary, NC) and all P-values were twosided.
Results

Patient characteristics
A total of 132,671 lung cancer patients were identified for this study, 114,451 with NSCLC (Table 1 ). Of these, 6389 (5.5% of all NSCLC patients) were <50 years of age. Median age of this younger subset was 46 years (range: 6-49). Most younger patients were White (3557 patients, or 55.7% of the group), which was a lower percentage than the age-over-50 cohort. The most prevalent histology was adenocarcinoma, which accounted for 57.9% of all young patients and was of a higher proportion than in older patients. Of this young patient population, 57.2% were diagnosed with Stage IV disease compared to 42. 
Univariate analysis
Cause specific survival for each baseline clinical variable in patients under age 50 was evaluated; these results are summarized in Table 2 . Female sex was associated with better median CSS (16 vs. 11 months, P < 0.0001 Fig. 1 ). Differential CSS was also seen with regard to race and ethnicity, with Asians having the highest median CSS estimate of 17 months. Patients diagnosed in later years (2006-2009) had a higher median CSS of 17 months: (12) (13) (14) this was significantly different (P < 0.0001) when compared to earlier eras (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) where median CSS was only 12 months. Expectedly, patients whose initial treatment consisted of potentially curative procedures such as surgery or radiation therapy had higher median CSS times. Similarly, patients with lower stage (i.e., potentially curable) disease also had higher median CSS compared to those with higher stage: stage IV -8 months, stage III -17 months, stage II -29 months, and stage I -median CSS not reached (Fig. 2) . Patients in the highest socioeconomic status quintiles (4 and 5) also had higher median CSS (16 months), as compared to those with the lowest quintiles (1 and 2: 11 months), with a P-value of <0.001. Finally, patients in the urban setting had a modest median CSS advantage over those in the rural setting (13 vs. 10 months, P = 0.0139).
Multivariate analysis
Variables associated with improved CCS for the entire population of NSCLC patients and those under age 50 were evaluated using separate Cox models. Tests for interactions for predictive variables were performed between the two age groups. These results are summarized in Table 3 . Within the younger patient cohort, most trends seen in the univariate analysis were still present after adjustment. The primary exception was that a trend for worse outcomes for patients from rural areas was no longer statistically significant for those under 50 years. For the overall cohort, age under 50 was associated with improved CSS, with a hazard ratio of 0.827 (P < 0.001). Trends toward improved survival were noted in groups diagnosed in later years, as compared to 1998-2001 for both the entire population and patients under 50. Female sex and socioeconomic status were predictive of an improved outcome for both cohorts as well. Evaluation of histology found that adenocarcinoma was associated with a modestly improved outcome in the entire population (HR 0.928, P < 0.001). This association was not statistically significant in the younger cohort (HR 0.987, P = 0.788). Significant interactions were identified between age and Hispanic race as well as between age and bronchioloalveolar carcinoma (BAC) histology. Specifically, young Hispanics had improved outcomes compared to older Hispanics with a HR for CSS of 0.78 vs. 0.90 for older Hispanics. Young patients with BAC had a HR of 0.85 compared to 0.65 in older patients with BAC. These interactions had a P-value of <0.001. Thus, BAC was not associated with better prognosis in younger patients, in contrast to older patients.
Discussion
Lung cancer is generally a disease of older patients. Past studies either had conflicting results on the differential survival of young NSCLC patients relative to older patients, or were limited by very small sample sizes. We performed this study to evaluate factors that may influence survival in patients younger than 50 years using a large statewide tumor registry to overcome sample size limitations. We found that several baseline clinical features (including female sex, Asian or Hispanic ethnicity, lower stage, initial treatment with curative intent, high socioeconomic status, but not adenocarcinoma histology) were independently associated with improved CSS in patients <50 years of age. Importantly, we found that age less than 50 years was also strong independent predictor of CSS. We believe that these results provide the most recent large-scale analysis of this specific patient cohort and can therefore serve as a suitable benchmark for future studies.
As noted, we report that age <50 appears to be an independent prognostic factor for better CSS. Similarly, a registry study of Japanese lung cancer patients aged 20-49 diagnosed between 1958 and 2003, and a SEER analysis of lung cancer patients less than age 50 also showed a trend for lower mortality among young adults [4, 19] . There are several possible explanations for this emerging observation. Young patients tend to receive more aggressive treatment than their older counterparts, which could have translated into better outcomes [3, 7] . There may also have been a higher rate of actionable mutations within the tumors of younger patients for which effective targeted therapy drugs are available. In a recent study of patients less than 40 years of age, driver oncogenes including EGFR activating mutations and EML4-ALK fusion were identified in 75% of cases [14] . It is known that these molecular alterations are particularly sensitive to specific tyrosine kinase inhibitors [14] . Notably, median survival in younger patients increased to 17 months for 2006-2009 as compared to 11 months in 1998-2005: interestingly, erlotinib was approved for refractory NSCLC in 2004.
Our study could not demonstrate that adenocarcinoma histology was a significant predictor of CSS relative to all other histologic groups in young patients, though it was associated with improved CSS for the entire NSCLC cohort. For BAC, a subset of adenocarcinoma, there was an association with improved outcome in older patients, but this was not present in younger patients. The reasons for this difference are unclear, but it is possible that there may be unseen imbalances in the distribution of molecular features across both age groups and histologic subtypes that could have influenced subsequent prognosis [15] .
When compared to other studies, our results show that certain clinical variables were consistently associated with survival, including age < 50 as well as gender and stage [3, 6, 11] . In a SEER analysis, five-year overall survival was significantly better in a group younger than 50 years of age (16.1% vs. 13.4%; P < .001), principally as a result of better survival in patients with presumably curable (localized or early stage) disease (48.7% vs. 35.4%; P < .001) [7] . Furthermore, these investigators reported that male sex was also an independent negative prognostic factor.
We also found that the proportion of cases of NSCLC in young patients had marginally decreased over time. This mirrors the observation from registry studies in Japan where the proportion of lung cancer patients aged 40-49 years dropped from 6.9% in 1994 to 4.2% in 2004 [16] . Similarly, in a Korean registry report, the mean age of lung cancer patients increased over successive time intervals (1990-1994, 1995-1999, 2000-2004, and 2005-2009 ) from 57.8 years to 62.5 years [17] .
Our work has several strengths. First, it has a large sample size, representing all lung cancer cases diagnosed in California from 1998 to 2009. By state statute, all cases require mandatory reporting of baseline variables and survival data. In addition, the ethnic diversity of the registry population enhances its potential to be generalizable to the entire NSCLC population and to detect differences between ethnic groups.
There are limitations to this study. Since the CCR is considered a regional (i.e., statewide) registry, it may not be readily applicable to other states that have different demographic features than California. Another limitation is the retrospective nature of the analysis which can introduce certain biases. Finally, the CCR does not collect all relevant clinical information such as molecular phenotypic information (which is becoming critical in systemic treatment selection for NSCLC), detailed treatment data, known risk factors such as smoking, as well other important prognostic variables such as weight loss, functional status, and comorbidity scores.
Conclusions
In conclusion, this large registry experience found that age < 50 years is an independent predictor of improved CSS (HR 0.827, P < 0.001) in the modern era. In addition, the proportion of young patients with NSCLC has decreased from 6.0% (1998-2001) to 5.0% (2006) (2007) (2008) (2009) . Importantly, in young patients BAC histology was not associated with improved survival as it is in the overall population with NSCLC. Finally, clinical variables independently prognostic for CSS were identified in the younger patient subgroup.
